Biocept, Inc.
BIOCQOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$525
P/E Ratio—
52W High$0.1
52W Low$0.0001
Biocept, Inc.（BIOCQ）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BIOCQ · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $25.86M | $61.25M | $27.46M | $5.53M |
| Cost of Revenue | $28.44M | $37.76M | $21.34M | $10.98M |
| Gross Profit | ($2.58M) | $23.48M | $6.12M | ($5.45M) |
| Gross Margin %(computed) | -9.99% | 38.34% | 22.30% | -98.56% |
| Operating Expenses | ||||
| R&D Expenses | $6.16M | $4.96M | $5.22M | $4.70M |
| G&A Expenses | $16.11M | $12.61M | $9.97M | $6.97M |
| Total Operating Expenses | $29.40M | $25.89M | $21.59M | $17.61M |
| Operating Income | ($31.98M) | ($2.41M) | ($15.47M) | ($23.06M) |
| Operating Margin %(computed) | -123.69% | -3.93% | -56.33% | -417.05% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.32M | $0.29M | $0.24M | $0.25M |
| Income Before Tax | ($32.21M) | ($2.70M) | ($17.81M) | ($25.14M) |
| Income Tax Expense | ($0.13M) | $0.13M | $0.00M | $0.00M |
| Net Income | ($32.09M) | ($2.82M) | ($17.81M) | ($25.14M) |
| Net Margin %(computed) | -124.09% | -4.61% | -64.84% | -454.69% |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-56.78 | $-5.73 | $-45.10 | $-365.01 |
| Wtd Avg Shares | 0.57M | 0.49M | 0.39M | 0.07M |
| EBITDA | ($30.24M) | ($0.88M) | ($16.57M) | ($24.11M) |
| EBITDA Margin %(computed) | -116.95% | -1.44% | -60.34% | -436.18% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · M
深入了解Biocept, Inc.
关于Biocept, Inc.（BIOCQ）损益表
Biocept, Inc.（BIOCQ）损益表数据来源于SEC Form 10-K及10-Q申报文件。2022财年，BIOCQ实现营收$0.03B，毛利润($0.00B)（毛利率-9.99%），净利润($0.03B)（净利率-124.09%）。
常见问题
BIOCQ · 4 问Biocept, Inc.（BIOCQ）2022财年营收为$0.03B，同比down57.8%。
BIOCQ revenueBIOCQ salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09